|
1.
|
Kitson J, Raven T, Jiang YP, et al: A
death-domain-containing receptor that mediates apoptosis. Nature.
384:372–375. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Marsters SA, Sheridan JP, Donahue CJ, et
al: Apo-3, a new member of the tumor necrosis factor receptor
family, contains a death domain and activates apoptosis and
NF-kappa B. Curr Biol. 6:1669–1676. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Chinnaiyan AM, O'Rourke K, Yu GL, et al:
Signal transduction by DR3, a death domain-containing receptor
related to TNFR-1 and CD95. Science. 274:990–992. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kaplan MJ, Ray D, Mo RR, Yung RL and
Richardson BC: TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate
CD4+ T cell killing of antigen-presenting macrophages. J
Immunol. 164:2897–2904. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kaptein A, Jansen M, Dilaver G, et al:
Studies on the interaction between TWEAK and the death receptor
WSL-1/TRAMP (DR3). FEBS Lett. 485:135–141. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Nakayama M, Ishidoh K, Kayagaki N, et al:
Multiple pathways of TWEAK-induced cell death. J Immunol.
168:734–743. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zhai Y, Ni J, Jiang GW, et al: VEGI, a
novel cytokine of the tumor necrosis factor family, is an
angiogenesis inhibitor that suppresses the growth of colon
carcinomas in vivo. FASEB J. 13:181–189. 1999.PubMed/NCBI
|
|
8.
|
Migone TS, Zhang J, Luo X, et al: TL1A is
a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Muppidi JR, Tschopp J and Siegel RM: Life
and death decisions: secondary complexes and lipid rafts in TNF
receptor family signal transduction. Immunity. 21:461–465. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Wen L, Zhuang L, Luo X and Wei P:
TL1A-induced NF-kappaB activation and c-IAP2 production prevent
DR3-mediated apoptosis in TF-1 cells. J Biol Chem. 278:39251–39258.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gout S, Morin C, Houle F and Huot J: Death
receptor-3, a new E-selectin counter-receptor that confers
migration and survival advantages to colon carcinoma cells by
triggering p38 and ERK MAPK activation. Cancer Res. 66:9117–9124.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Pitti RM, Marsters SA, Lawrence DA, et al:
Genomic amplification of a decoy receptor for Fas ligand in lung
and colon cancer. Nature. 396:699–703. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bai C, Connolly B, Metzker ML, et al:
Overexpression of M68/DcR3 in human gastrointestinal tract tumors
independent of gene amplification and its location in a four-gene
cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zhang J, Salcedo TW, Wan X, et al:
Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin
Invest. 107:1459–1468. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Wu Y, Han B, Sheng H, et al: Clinical
significance of detecting elevated serum DcR3/TR6/M68 in malignant
tumor patients. Int J Cancer. 105:724–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hsu TL, Chang YC, Chen SJ, et al:
Modulation of dendritic cell differentiation and maturation by
decoy receptor 3. J Immunol. 168:4846–4853. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hsu TL, Wu YY, Chang YC, et al:
Attenuation of Th1 response in decoy receptor 3 transgenic mice. J
Immunol. 175:5135–5145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hsu MJ, Lin WW, Tsao WC, et al: Enhanced
adhesion of monocytes via reverse signaling triggered by decoy
receptor 3. Exp Cell Res. 292:241–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Wu SF, Liu TM, Lin YC, et al:
Immunomodulatory effect of decoy receptor 3 on the differentiation
and function of bone marrow-derived dendritic cells in nonobese
diabetic mice: from regulatory mechanism to clinical implication. J
Leukoc Biol. 75:293–306. 2004.
|
|
22.
|
Bodmer JL, Burns K, Schneider P, et al:
TRAMP, a novel apoptosis-mediating receptor with sequence homology
to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity.
6:79–88. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Tartaglia LA, Ayres TM, Wong GH and
Goeddel DV: A novel domain within the 55 kd TNF receptor signals
cell death. Cell. 74:845–853. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Simonet WS, Lacey DL, Dunstan CR, et al:
Osteoprotegerin: a novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Tan KB, Harrop J, Reddy M, et al:
Characterization of a novel TNF-like ligand and recently described
TNF ligand and TNF receptor superfamily genes and their
constitutive and inducible expression in hematopoietic and
non-hematopoietic cells. Gene. 204:35–46. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Haridas V, Shrivastava A, Su J, et al:
VEGI, a new member of the TNF family activates nuclear factor-kappa
B and c-Jun N-terminal kinase and modulates cell growth. Oncogene.
18:6496–6504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee
JM: Characterization of cis-regulatory elements of the vascular
endothelial growth inhibitor gene promoter. Biochem J. 388:913–920.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zhai Y, Yu J, Iruela-Arispe L, et al:
Inhibition of angiogenesis and breast cancer xenograft tumor growth
by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer.
82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Chew LJ, Pan H, Yu J, et al: A novel
secreted splice variant of vascular endothelial cell growth
inhibitor. FASEB J. 16:742–744. 2002.PubMed/NCBI
|
|
30.
|
Lasky LA: Selectins: interpreters of
cell-specific carbohydrate information during inflammation.
Science. 258:964–969. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Higai K, Shimamura A and Matsumoto K:
Amadori-modified glycated albumin predominantly induces E-selectin
expression on human umbilical vein endothelial cells through NADPH
oxidase activation. Clin Chim Acta. 367:137–143. 2006. View Article : Google Scholar
|
|
32.
|
Collins T, Read MA, Neish AS, Whitley MZ,
Thanos D and Maniatis T: Transcriptional regulation of endothelial
cell adhesion molecules: NF-kappa B and cytokine-inducible
enhancers. FASEB J. 9:899–909. 1995.PubMed/NCBI
|
|
33.
|
Subramaniam M, Koedam JA and Wagner DD:
Divergent fates of P- and E-selectins after their expression on the
plasma membrane. Mol Biol Cell. 4:791–801. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Steegmaier M, Levinovitz A, Isenmann S, et
al: The E-selectin-ligand ESL-1 is a variant of a receptor for
fibroblast growth factor. Nature. 373:615–620. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Constantin G: PSGL-1 as a novel
therapeutic target. Drug News Perspect. 17:579–586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Romano SJ and Slee DH: Targeting selectins
for the treatment of respiratory diseases. Curr Opin Investig
Drugs. 2:907–913. 2001.PubMed/NCBI
|
|
37.
|
Bock D, Philipp S and Wolff G: Therapeutic
potential of selectin antagonists in psoriasis. Expert Opin
Investig Drugs. 15:963–979. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Sfikakis PP and Mavrikakis M: Adhesion and
lymphocyte costimulatory molecules in systemic rheumatic diseases.
Clin Rheumatol. 18:317–327. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Witz IP: Tumor-microenvironment
interactions: the selectin-selectin ligand axis in
tumor-endothelium cross talk. Cancer Treat Res. 130:125–140. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Laferriere J, Houle F and Huot J:
Regulation of the metastatic process by E-selectin and
stress-activated protein kinase-2/p38. Ann NY Acad Sci.
973:562–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Witz IP: The involvement of selectins and
their ligands in tumor-progression. Immunol Lett. 104:89–93. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Romano SJ: Selectin antagonists:
therapeutic potential in asthma and COPD. Treat Respir Med.
4:85–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Mauri DN, Ebner R, Montgomery RI, et al:
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha
are ligands for herpesvirus entry mediator. Immunity. 8:21–30.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Harrop JA, McDonnell PC, Brigham-Burke M,
et al: Herpesvirus entry mediator ligand (HVEM-L), a novel ligand
for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29
cell growth. J Biol Chem. 273:27548–27556. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Murphy M, Walter BN, Pike-Nobile L, et al:
Expression of the lymphotoxin beta receptor on follicular stromal
cells in human lymphoid tissues. Cell Death Differ. 5:497–505.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Stopfer P, Mannel DN and Hehlgans T:
Lymphotoxin-beta receptor activation by activated T cells induces
cytokine release from mouse bone marrow-derived mast cells. J
Immunol. 172:7459–7465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Yu P, Lee Y, Liu W, et al: Priming of
naive T cells inside tumors leads to eradication of established
tumors. Nat Immunol. 5:141–149. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Tamada K, Shimozaki K, Chapoval AI, et al:
LIGHT, a TNF-like molecule, costimulates T cell proliferation and
is required for dendritic cell-mediated allogeneic T cell response.
J Immunol. 164:4105–4110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Yu P and Fu YX: Targeting tumors with
LIGHT to generate metastasis-clearing immunity. Cytokine Growth
Factor Rev. 19:285–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Itoh N, Yonehara S, Ishii A, et al: The
polypeptide encoded by the cDNA for human cell surface antigen Fas
can mediate apoptosis. Cell. 66:233–243. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Suda T, Takahashi T, Golstein P and Nagata
S: Molecular cloning and expression of the Fas ligand, a novel
member of the tumor necrosis factor family. Cell. 75:1169–1178.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Van Parijs L and Abbas AK: Role of
Fas-mediated cell death in the regulation of immune responses. Curr
Opin Immunol. 8:355–361. 1996.PubMed/NCBI
|
|
53.
|
Griffith TS and Ferguson TA: The role of
FasL-induced apoptosis in immune privilege. Immunol Today.
18:240–244. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Muschen M, Moers C, Warskulat U, Even J,
Niederacher D and Beckmann MW: CD95 ligand expression as a
mechanism of immune escape in breast cancer. Immunology. 99:69–77.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
O'Connell J, Bennett MW, O'Sullivan GC, et
al: Fas ligand expression in primary colon adenocarcinomas:
evidence that the Fas counterattack is a prevalent mechanism of
immune evasion in human colon cancer. J Pathol. 186:240–246.
1998.PubMed/NCBI
|
|
56.
|
Koyama S, Koike N and Adachi S: Fas
receptor counterattack against tumor-infiltrating lymphocytes in
vivo as a mechanism of immune escape in gastric carcinoma. J Cancer
Res Clin Oncol. 127:20–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Bennett MW, O'Connell J, O'Sullivan GC, et
al: The Fas counterattack in vivo: apoptotic depletion of
tumor-infiltrating lymphocytes associated with Fas ligand
expression by human esophageal carcinoma. J Immunol. 160:5669–5675.
1998.
|
|
58.
|
Reimer T, Herrnring C, Koczan D, et al:
FasL:Fas ratio – a prognostic factor in breast carcinomas. Cancer
Res. 60:822–828. 2000.
|
|
59.
|
Li W, Zhang C, Chen C and Zhuang G:
Correlation between expression of DcR3 on tumor cells and
sensitivity to FasL. Cell Mol Immunol. 4:455–460. 2007.PubMed/NCBI
|
|
60.
|
Bu R, Borysenko CW, Li Y, Cao L, Sabokbar
A and Blair HC: Expression and function of TNF-family proteins and
receptors in human osteoblasts. Bone. 33:760–770. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Screaton GR, Xu XN, Olsen AL, et al: LARD:
a new lymphoid-specific death domain containing receptor regulated
by alternative pre-mRNA splicing. Proc Natl Acad Sci USA.
94:4615–4619. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Wang EC, Kitson J, Thern A, Williamson J,
Farrow SN and Owen MJ: Genomic structure, expression, and
chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3,
TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics. 53:59–63. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N,
Zhao H and Brodeur GM: Expression of Apo-3 and Apo-3L in primitive
neuroectodermal tumours of the central and peripheral nervous
system. Eur J Cancer. 38:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Warzocha K, Ribeiro P, Charlot C, Renard
N, Coiffier B and Salles G: A new death receptor 3 isoform:
expression in human lymphoid cell lines and non-Hodgkin's
lymphomas. Biochem Biophys Res Commun. 242:376–379. 1998.PubMed/NCBI
|
|
65.
|
Chen G and Luo D: Expression of decoy
receptor 3 in liver tissue microarrays. Natl Med J India.
21:275–278. 2008.PubMed/NCBI
|
|
66.
|
Li L, Hu J, Zhao R and Yue Z: [Expression
of DcR3 protein and its significance in laryngeal carcinoma]. Lin
Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 21:537–539. 2007.
|
|
67.
|
Liang QL, Wang BR and Li GH: DcR3 and
survivin are highly expressed in colorectal carcinoma and closely
correlated to its clinicopathologic parameters. J Zhejiang Univ Sci
B. 10:675–682. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Ho CH, Chen CL, Li WY and Chen CJ: Decoy
receptor 3, upregulated by Epstein-Barr virus latent membrane
protein 1, enhances nasopharyngeal carcinoma cell migration and
invasion. Carcinogenesis. 30:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Chen PH and Yang CR: Decoy receptor 3
expression in AsPC-1 human pancreatic adenocarcinoma cells via the
phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent
pathway. J Immunol. 181:8441–8449. 2008. View Article : Google Scholar
|
|
70.
|
Macher-Goeppinger S, Aulmann S, Wagener N,
et al: Decoy receptor 3 is a prognostic factor in renal cell
cancer. Neoplasia. 10:1049–1056. 2008.PubMed/NCBI
|
|
71.
|
Li H, Zhang L, Lou H, et al:
Overexpression of decoy receptor 3 in precancerous lesions and
adenocarcinoma of the esophagus. Am J Clin Pathol. 124:282–287.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Simon I, Liu Y, Krall KL, et al:
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3
for diagnosis and early detection of ovarian cancer. Gynecol Oncol.
106:112–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Zhang L, Zhang Y, Yang X and Lv Z: Lupeol,
a dietary triterpene, inhibited growth, and induced apoptosis
through down-regulation of DR3 in SMMC7721 cells. Cancer Invest.
27:163–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Hayashi S, Miura Y, Nishiyama T, et al:
Decoy receptor 3 expressed in rheumatoid synovial fibroblasts
protects the cells against Fas-induced apoptosis. Arthritis Rheum.
56:1067–1075. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Prehn JL, Thomas LS, Landers CJ, Yu QT,
Michelsen KS and Targan SR: The T cell costimulator TL1A is induced
by FcgammaR signaling in human monocytes and dendritic cells. J
Immunol. 178:4033–4038. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Wroblewski VJ, Witcher DR, Becker GW, et
al: Decoy receptor 3 (DcR3) is proteolytically processed to a
metabolic fragment having differential activities against Fas
ligand and LIGHT. Biochem Pharmacol. 65:657–667. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and
Kwon BS: A newly identified member of tumor necrosis factor
receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J
Biol Chem. 274:13733–13736. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL
and Lin WW: Soluble decoy receptor 3 induces angiogenesis by
neutralization of TL1A, a cytokine belonging to tumor necrosis
factor superfamily and exhibiting angiostatic action. Cancer Res.
64:1122–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Tian F, Liang PH and Li LY: Inhibition of
endothelial progenitor cell differentiation by VEGI. Blood.
113:5352–5360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Murtaza I, Adhami VM, Hafeez BB, Saleem M
and Mukhtar H: Fisetin, a natural flavonoid, targets chemoresistant
human pancreatic cancer AsPC-1 cells through DR3-mediated
inhibition of NF-kappaB. Int J Cancer. 125:2465–2473. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Gill RM and Hunt JS: Soluble receptor
(DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human
cytotrophoblast cells against LIGHT-mediated apoptosis. Am J
Pathol. 165:309–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
Chen G and Luo D: Over-expression of decoy
receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med
Sci. 113:297–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83.
|
Wu YL, Yu JX, Shen HW, Han B and Gao SL:
[Clinical significance and correlation between elevated serum TR6
and lympho-metastasis in gastric cancer]. Zhonghua Wai Ke Za Zhi.
41:928–931. 2003.
|
|
84.
|
Wu Y, Guo E, Yu J and Xie Q: High DcR3
expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol.
31:79–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85.
|
Wu Y, Guo E, Yu J, Xie Q and Chen J: High
DcR3 expression predicts stage pN2 in gastric cancer.
Hepatogastroenterology. 54:2172–2176. 2007.PubMed/NCBI
|
|
86.
|
Roth W, Isenmann S, Nakamura M, et al:
Soluble decoy receptor 3 is expressed by malignant gliomas and
suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer
Res. 61:2759–2765. 2001.PubMed/NCBI
|
|
87.
|
Shen HW, Gao SL, Wu YL and Peng SY:
Overexpression of decoy receptor 3 in hepatocellular carcinoma and
its association with resistance to Fas ligand-mediated apoptosis.
World J Gastroenterol. 11:5926–5930. 2005.PubMed/NCBI
|
|
88.
|
Chen G, Luo DZ, Wang Y, Liao ZL and Zhang
MY: [Relationship between expression of decoy receptor 3 and
apoptosis in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za
Zhi. 36:113–117. 2007.
|
|
89.
|
Chang YC, Hsu TL, Lin HH, et al:
Modulation of macrophage differentiation and activation by decoy
receptor 3. J Leukoc Biol. 75:486–494. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
90.
|
Shi G, Wu Y, Zhang J and Wu J: Death decoy
receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.
J Immunol. 171:3407–3414. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
91.
|
Tian F, Grimaldo S, Fujita M, Cutts J,
Vujanovic NL and Li LY: The endothelial cell-produced
antiangiogenic cytokine vascular endothelial growth inhibitor
induces dendritic cell maturation. J Immunol. 179:3742–3751. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
92.
|
Morishige T, Yoshioka Y, Inakura H, et al:
Creation of a LIGHT mutant with the capacity to evade the decoy
receptor for cancer therapy. Biomaterials. 31:3357–3363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
93.
|
Wu CF, Ma ZS, Wang XL, et al: [Preparation
and identification of monoclonal antibodies against human DcR3]. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 24:139–141. 2008.
|
